05.12.2019 |
Carl W. Baker, MD; Adam R. Glassman, MS; Wesley T. Beaulieu, PhD; et al
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity
Intravitreous injections of antivascular endothelial growth factor agents are effective for treating diabetic macular edema (DME) involving the center of the macula (center-involved DME [CI-DME]) with visual acuity impairment (20/32 or worse).
The best approach to treating patients with CI-DME and good visual acuity (20/25 or better) is unknown.
compare vision loss at 2 years among eyes initially managed with aflibercept, laser photocoagulation, or observation.
Randomized clinical trial conducted at 91 US and Canadian sites among 702 adults with type 1 or type 2 diabetes.
Participants had 1 study eye with CI-DME and visual acuity of 20/25 or better. The first participant was randomized on November 8, 2013, and the final date of follow-up was September 11, 2018.
JAMA. 2019;321(19):1880-1894. doi:10.1001/jama.2019.5790